Bech E, Orntoft T F, Andersen L P, Skinhøj P, Jakobsen J
Department of Neurology, Aarhus University Hospital, Denmark.
J Neuroimmunol. 1997 Jan;72(1):59-66. doi: 10.1016/s0165-5728(96)00145-2.
It has been suggested that antibodies against GM1 are involved in the pathogenesis of the Guillain-Barré syndrome (GBS). Recently, we have developed a standardized ELISA assay for anti-GM1 antibodies of IgM type well-suited for longitudinal patient studies. The relationship between serum antibodies against GM1 and Campylobacter jejuni was investigated in patients with GBS and in patients with C. jejuni infection. Patients with a short-lasting anti-GM1 elevation had a fast recovery, whereas patients with slow recovery had a long-lasting anti-GM1 elevation. A linear relationship was found between significant clinical recovery and the time until the anti-GM1 peak was halved (R = 0.9, p < 0.01). The absolute level of anti-GM1 did not predict the length of the recovery nor was the level of anti-GM1 related to the clinical disability at its nadir. Our data indicate that monitoring of the IgM anti-GM1 level can predict clinical recovery in GBS patients.
有人提出，抗GM1抗体与吉兰-巴雷综合征（GBS）的发病机制有关。最近，我们开发了一种标准化的ELISA检测方法，用于检测IgM型抗GM1抗体，非常适合对患者进行纵向研究。我们研究了GBS患者和空肠弯曲菌感染患者血清抗GM1抗体与空肠弯曲菌之间的关系。抗GM1短暂升高的患者恢复较快，而恢复缓慢的患者抗GM1持续升高。在显著的临床恢复与抗GM1峰值减半所需时间之间发现了线性关系（R = 0.9，p < 0.01）。抗GM1的绝对水平不能预测恢复时间，抗GM1水平也与最低点时的临床残疾程度无关。我们的数据表明，监测IgM抗GM1水平可以预测GBS患者的临床恢复情况。
